8.60 0.00 (0.00%)
After hours: 4:51PM EDT
|Bid||8.58 x 1000|
|Ask||8.64 x 4000|
|Day's Range||8.53 - 8.74|
|52 Week Range||4.86 - 13.21|
|Beta (3Y Monthly)||2.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.56|
CLEVELAND, May 22, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that the clinical team at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis has treated its 1,000th patient using MRIdian MR-guided radiation therapy. Siteman Cancer Center helped pioneer MR-guided radiation therapy, becoming the first center to treat patients with MRIdian in January 2014.
CLEVELAND , May 16, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in the Jefferies 2019 Global Healthcare Conference in New York, New York . Scott ...
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
ViewRay (VRAY) delivered earnings and revenue surprises of -54.55% and -3.30%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Oakwood Village, Ohio-based company said it had a loss of 34 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
CLEVELAND , May 2, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the first quarter ended March 31, 2019 . First Quarter 2019 Highlights: Received 7 new orders ...
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
26 Clinical Presentations and Posters Highlight Benefits of MRI-Guided Radiation Therapy Across Applications and Growing Use of Adaptive Therapy CLEVELAND , April 23, 2019 /PRNewswire/ -- ViewRay, Inc. ...
CLEVELAND, April 18, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that the company has partnered with Minogue Medical Inc., a leading Canadian distributor of surgical devices, operating room disposables, hospital equipment, and simulators for medical education. As part of the exclusive distribution agreement, Minogue Medical will market, sell, and support ViewRay's MRIdian MRI-guided radiation therapy system throughout Canada.
CLEVELAND, April 17, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) and Device Technologies Australia Pty Ltd (Device Technologies) announced today a partnership in which Device Technologies, the largest independent distributor in Australasia, will market, sell, and support ViewRay's MRIdian MRI-guided radiation therapy system. "Device Technologies is the ideal partner to bring the benefits of the MRIdian System to one of the biggest and best healthcare markets in the world," said Jim Alecxih, Chief Commercial Officer at ViewRay. MRIdian provides continuous high-contrast imaging of soft tissue during radiation therapy treatment to help clinicians position the patient, track tumor and anatomical motion, and accurately target treatment.
ViewRay will hold a conference call to discuss results on Thursday, May 2, 2019 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 8616638.
CLEVELAND, April 11, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today the publication of a retrospective analysis of outcomes for the stereotactic treatment of locally advanced pancreatic cancer using precise, high-dose MRI-guided radiation therapy delivered with MRIdian's on-table adaptive dose planning system. The study, published in Cancer Medicine, and led by Soumon Rudra, M.D. from Washington University in St. Louis, demonstrated enhanced overall survival while resulting in lower levels of toxicity compared to lower-dose, mostly non-adaptive treatment.
ViewRay, Inc.'s (NASDAQ:VRAY) most recent earnings announcement in December 2018 indicated company earnings became less negative compared to the previous year's level - great news for investors Investors may findRead More...
The Oakwood Village, Ohio-based company said it had a loss of 17 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
CLEVELAND , March 14, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the fourth quarter and full year ended December 31, 2018 . Full Year 2018 Highlights: Total ...
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / ViewRay, Inc. (NASDAQ: VRAY ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 14, 2019, 2018 at 4:30 PM ...